Seattle Genetics Offers Data Supporting Antibody-Drug Conjugate, Novel Immuno-Oncology Programs at AACR Meeting

Seattle Genetics, Inc. SGEN today highlighted multiple data presentations that support several of the company's antibody-drug conjugate (ADC) and immuno-oncology programs featured at the upcoming 107th Annual Meeting of the American Association for Cancer Research (AACR) being held April 16 through 20, 2016 in New Orleans, LA. The presentations describe preclinical data with SGN-LIV1A and SEA-CD40, which are in ongoing clinical trials, and highlight two preclinical programs, a novel ADC for the treatment of multiple myeloma (SGN-CD352A) and a small molecule that enhances T-cell mediated antitumor activity (2-fluorofucose). Additional data highlight the growing body of knowledge regarding the ability of auristatin-based ADCs, including ADCETRIS (brentuximab vedotin), to initiate immunogenic cell death, supporting evaluation in combination with checkpoint inhibitors. "Our ADC expertise currently empowers a robust pipeline of more than a dozen clinical and preclinical programs," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics. "At AACR, we will be presenting preclinical data that demonstrate encouraging activity with SGN-LIV1A, an ADC in phase 1 clinical development for breast cancer, and the preclinical development of a novel ADC for multiple myeloma, SGN-CD352A, which uses our newest ADC technology. We will also highlight the progress we have made in the important field of immuno-oncology, demonstrating that auristatin-based ADCs may be particularly well suited for combination with checkpoint inhibitors and presenting exciting preclinical data for SEA-CD40 and a small molecule, 2-fluorofucose." Multiple presentations are being featured at AACR that highlight advances with Seattle Genetics' proprietary ADC and empowered antibody pipeline and research programs. Abstracts can be found at www.aacr.org and include the following: Preclinical data from a novel ADC candidate SGN-CD352A for multiple myeloma will be highlighted in a poster presentation on Monday, April 18, 2016 (Abstract #1195). SGN-CD352A utilizes Seattle Genetics' newest ADC technology and is composed of an anti-CD352 antibody attached to a highly potent cytotoxic DNA-crosslinking agent called a pyrrolobenzodiazepine (PBD) dimer via a proprietary site-specific conjugation technology to a monoclonal antibody with engineered cysteines (EC-mAb). SGN-LIV1A will be highlighted in a poster presentation on Tuesday, April 19, 2016 (Abstract #2966) focusing on the potential of combination use with standard of care chemotherapeutic agents, including doxorubicin, paclitaxel (Abraxane), carboplatin and various kinase inhibitors, for the treatment of breast cancer. SGN-LIV1A is in a phase 1 trial for the treatment of LIV-1-expressing metastatic breast cancer. A preclinical analysis will highlight the novel small molecule, 2-fluorofucose (2FF) in a poster presentation on Tuesday, April 19, 2016 (Abstract #4005). 2FF blocks cellular incorporation of a sugar (fucose) and has been shown in preclinical studies to stimulate T-cell receptor signaling leading to enhanced activation of dendritic cells. The path of SEA-CD40 from research to clinical development will be highlighted in a poster presentation on Wednesday, April 20, 2016 (Abstract #4994). SEA-CD40 is in an ongoing phase 1 trial for patients with advanced malignancies. SEA-CD40 is a novel immuno-oncology agent targeted to CD40 utilizing Seattle Genetics' proprietary sugar-engineered antibody (SEA) technology to produce a non-fucosylated antibody. Preclinical data evaluating brentuximab vedotin (ADCETRIS) immune activity will be presented in a poster presentation on Wednesday, April 20, 2016 (Abstract #4914). The preclinical data being presented demonstrate that brentuximab vedotin treated tumor cells may initiate an antitumor immune response and supports combination strategies with immuno-oncology regimens, such as the ongoing phase 1/2 clinical trials evaluating ADCETRIS and nivolumab (Opdivo) in relapsed Hodgkin and non-Hodgkin lymphoma.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!